[评论] 缩短治疗时间以加速消除丙型肝炎
摘要
针对丙型肝炎病毒（HCV）感染的简单口服直接抗病毒治疗已改变了临床管理方式，并为消除丙型肝炎铺平了道路。1 第一种泛基因型固定剂量联合方案——索磷布韦–维帕他韦——于2016年获批使用，第二种——格卡瑞韦–哌仑他韦——于2017年紧随其后获批。两种被推荐为一线HCV治疗方案，适用于伴或不伴代偿性肝硬化的患者，两者共享几个重要特征——高效、耐受性良好、口服给药、每日一次——但在药片负担、治疗持续时间和可获得性方面有所不同，其中索磷布韦–维帕他韦疗程为12周（每日一片；有仿制药可用），而格卡瑞韦–哌仑他韦疗程为8周（每日三片；受专利保护）。
English
Simple oral direct-acting antiviral treatment for hepatitis C virus (HCV) infection has transformed clinical management and paved the way for elimination.1 The first pan-genotypic fixed-dose combination regimen, sofosbuvir–velpatasvir, was approved for use in 2016, with the second, glecaprevir–pibrentasvir, following in 2017. Both recommended first-line HCV treatments for people with or without compensated cirrhosis share several important features—high efficacy, excellent tolerability, oral administration, once daily dosing—but differ by pill burden, treatment duration, and availability, with sofosbuvir–velpatasvir prescribed for 12 weeks (one tablet daily; available as a generic formulation) and glecaprevir–pibrentasvir for 8 weeks (three tablets daily; under patent protection).